Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma
NCT05813327Phase 1Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Mar 2024
- Primary completion
- Apr 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of Pegargiminase in soft tissue sarcoma (STS) (2 arms), sponsored by Washington University School of Medicine. Primary endpoints: Treatment-related serious adverse event rate at 14 weeks and Recommended Phase II dose at 7 weeks. Started Mar 2024; status: terminated.
02
Drugs
Pegargiminase
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT05813327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05813327.